Stay updated on Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the number of patients enrolled in the study evaluating the combination therapy of nab-paclitaxel and pembrolizumab for advanced non-small cell lung cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:22:06.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now includes specific inclusion and exclusion criteria for participants.
    Difference
    26%
    Check dated 2024-05-22T21:22:11.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:28:53.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.